|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,431.00 JPY | +1.08% |
|
-3.25% | -19.00% |
| 04-13 | Cosmos Pharmaceutical's Nine-Month Profit Rises 1.8% | MT |
| 04-13 | Cosmos Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2026 | CI |
Company Valuation: COSMOS Pharmaceutical Corporation
Data adjusted to current consolidation scope
| Fiscal Period: May | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 603,094 | 483,107 | 525,081 | 502,890 | 700,001 | 504,235 | - | - |
| Change | - | -19.9% | 8.69% | -4.23% | 39.2% | -27.97% | - | - |
| Enterprise Value (EV) 1 | 553,560 | 450,132 | 497,354 | 477,918 | 692,920 | 483,955 | 473,686 | 465,844 |
| Change | - | -18.68% | 10.49% | -3.91% | 44.99% | -30.16% | -2.12% | -1.66% |
| P/E | 22.2x | 20.9x | 22.1x | 20.6x | 22.6x | 15.8x | 15.3x | 14.5x |
| PBR | 3.54x | 2.54x | 2.49x | 2.17x | 2.72x | 1.78x | 1.62x | 1.48x |
| PEG | - | -1.4x | 7.98x | 7.61x | 0.8x | 5.5x | 4.47x | 2.67x |
| Capitalization / Revenue | 0.83x | 0.64x | 0.63x | 0.52x | 0.69x | 0.46x | 0.43x | 0.4x |
| EV / Revenue | 0.76x | 0.6x | 0.6x | 0.5x | 0.69x | 0.44x | 0.4x | 0.37x |
| EV / EBITDA | 11.8x | 10x | 10.5x | 9.29x | 11.1x | 7.29x | 6.76x | 6.28x |
| EV / EBIT | 16.7x | 15.1x | 16.5x | 15.2x | 17.1x | 11.5x | 10.8x | 10.1x |
| EV / FCF | 65.2x | -39.1x | 93.5x | -222x | -807x | 111x | 71.4x | 58.4x |
| FCF Yield | 1.53% | -2.56% | 1.07% | -0.45% | -0.12% | 0.9% | 1.4% | 1.71% |
| Dividend per Share 2 | 35 | 40 | 50 | 60 | 70 | 75.97 | 81.81 | 88.12 |
| Rate of return | 0.46% | 0.66% | 0.75% | 0.95% | 0.79% | 1.19% | 1.29% | 1.39% |
| EPS 2 | 342.9 | 292.4 | 300.5 | 308.6 | 390.9 | 402.1 | 415.8 | 438.5 |
| Distribution rate | 10.2% | 13.7% | 16.6% | 19.4% | 17.9% | 18.9% | 19.7% | 20.1% |
| Net sales 1 | 726,424 | 755,414 | 827,697 | 964,989 | 1,011,390 | 1,095,472 | 1,178,476 | 1,259,783 |
| EBITDA 1 | 46,932 | 44,906 | 47,496 | 51,425 | 62,633 | 66,378 | 70,114 | 74,208 |
| EBIT 1 | 33,147 | 29,796 | 30,128 | 31,501 | 40,404 | 42,057 | 43,667 | 45,898 |
| Net income 1 | 27,156 | 23,155 | 23,797 | 24,454 | 30,978 | 31,868 | 32,961 | 34,755 |
| Net Debt 1 | -49,534 | -32,975 | -27,727 | -24,972 | -7,081 | -20,280 | -30,548 | -38,391 |
| Reference price 2 | 7,615.00 | 6,100.00 | 6,630.00 | 6,345.00 | 8,832.00 | 6,362.00 | 6,362.00 | 6,362.00 |
| Nbr of stocks (in thousands) | 79,198 | 79,198 | 79,198 | 79,258 | 79,257 | 79,257 | - | - |
| Announcement Date | 7/12/21 | 7/11/22 | 7/10/23 | 7/12/24 | 7/11/25 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.82x | 0.44x | 7.29x | 1.19% | 3.12B | |
| 22.83x | 0.38x | 5.89x | 2.15% | 6.33B | |
| 16.17x | 0.46x | 6.66x | 1.29% | 3.27B | |
| 13.17x | 0.46x | 5.78x | 3.57% | 2.75B | |
| 19.45x | 0.75x | 10.44x | 1.55% | 2.16B | |
| 13.4x | 0.4x | 3.8x | 3.78% | 1.28B | |
| 17.41x | 0.51x | 6.95x | 4.1% | 364M | |
| Average | 16.89x | 0.48x | 6.69x | 2.52% | 2.76B | |
| Weighted average by Cap. | 18.08x | 0.46x | 6.62x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 3349 Stock
- Valuation COSMOS Pharmaceutical Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
